Business Context and Reporting Period
This Form 8-K, dated January 20, 2023, is filed by Health Sciences Acquisitions Corporation 2 (HSAC2), a Cayman Islands exempted company and emerging growth company. The filing addresses an upcoming extraordinary general meeting of shareholders scheduled for January 24, 2023. The primary purpose of the meeting is to vote on a proposed business combination with Orchestra BioMed, Inc.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The only quantitative data disclosed relates to shareholder redemption activity:
- Redemption Requests: As of January 23, 2023, HSAC2 received requests to redeem 1,597,888 ordinary shares.
- Redemption Value: Shareholders are entitled to their pro rata portion of funds held in the trust account established at the time of the initial public offering.
Material Changes
The material change reported is the accumulation of shareholder redemption requests in anticipation of the business combination vote. The filing notes that the business combination was previously disclosed in a proxy statement/prospectus dated December 16, 2022.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the timeline for the shareholder vote on the merger with Orchestra BioMed, Inc. via a subsidiary, HSAC Olympus Merger Sub, Inc.
Risks and Contingencies: The success of the business combination is contingent upon shareholder approval at the General Meeting. The significant number of redemption requests (1,597,888 shares) represents a potential reduction in the cash available to the combined entity post-transaction, as these funds will be returned to redeeming shareholders rather than remaining in the trust.
Key Facts for Investor Verification
- Verify the total number of outstanding shares to calculate the percentage of shares being redeemed.
- Confirm the final cash balance in the trust account after processing the 1,597,888 redemption requests.
- Review the December 16, 2022 proxy statement/prospectus for the full terms of the business combination with Orchestra BioMed, Inc.
- Monitor the outcome of the shareholder vote scheduled for January 24, 2023.